HK inno.en K-Cap, obtains product approval in 6 Central and South American countries

HK inno.N announced on the 2nd that its new drug for gastroesophageal reflux disease, ‘K-Cap’, has obtained product approval in six Central and South American countries, including Colombia.

The Central and South American countries that have recently received approval for K-Cap (ingredient name: tegoprazan) are ▲Dominican Republic ▲Nicaragua ▲Honduras ▲Guatemala ▲El Salvador ▲Colombia.

K-Cap has so far exported technology or finished products to 18 countries in Central and South America. Following Mexico and Peru last year, it was recently launched in Chile, and is scheduled to be launched in 6 countries within the year.

HK inno.N and its partner company ‘Carnot’, which signed an export contract with 17 Central and South American countries excluding Brazil, are actively marketing and expanding the base of K-CAP (local product name ‘Ki-CAB’) in the Central and South American market. Since last year, they have been holding academic conferences for medical professionals in Korea and Central and South America, and this year, medical professionals from Mexico and Colombia visited Korea to share the latest knowledge on the current status of gastroesophageal reflux disease treatment in Mexico and various treatment options including K-CAP.

Kwak Dal-won, CEO of HK inno.N, said, “Based on the demand and positive response from the Central and South American markets, we are accelerating K-Cap’s advance into the Central and South American markets.”

“K-Cap has established itself as one of the top 10 peptic ulcer treatment drugs in Mexico in just seven months since its launch in the country, and we expect it to continue to grow this year to enter the top five in the market,” said Guy Sean Carnot, Chairman of the Company. “Our goal is to launch K-Cap in all contracted countries by 2025 and become the number one sales, specialized digestive medicine brand in Central and South America.”

K-Cab, the 30th domestic new drug, is a new drug for gastroesophageal reflux disease in the P-CAB (potassium competitive acid blocker) series. Its characteristics include that it takes effect quickly within 1 hour after taking it, and that it has secured efficacy and safety even when taken for long periods of up to 6 months. Since its launch in Korea in 2019, it has recorded a total of 617.4 billion won in outpatient prescription sales as of July 2024, ranking first in the domestic peptic ulcer treatment market for 4 consecutive years.